Results 111 to 120 of about 1,912 (177)

A Landmark Case of Childhood Glaucoma Care in Bangladesh: Gonioscopy-Assisted Transluminal Trabeculotomy in Primary Congenital Glaucoma. [PDF]

Cureus
Iqbal MI, Osman F.
europepmc   +1 more source

Prescribing carbonic anhydrase inhibitors to patients with "sulfa" antibiotics allergy: do we dare? [PDF]

Eye (Lond)
Quintanilla R, van Leeuwen L, Sharma A, Chang TC, Hodapp E, McSoley J, Grajewski A, Bitrian E.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Brinzolamide

Expert Opinion on Pharmacotherapy, 2008
Primary open-angle glaucoma is a multifactorial optic neuropathy characterized by the progressive loss of retinal ganglion cells and their axons. However, the primary risk factor is elevated intraocular pressure (IOP), which can damage the optic nerve head (ONH) and until now was the only treatable risk factor.
openaire   +3 more sources

Preclinical Overview of Brinzolamide

Survey of Ophthalmology, 2000
The development of topically active carbonic anhydrase inhibitors (CAIs) is a significant recent achievement in glaucoma medical treatment. Brinzolamide, the newest topical CAI, exhibits selectivity, high affinity, and potent inhibitory activity for the carbonic anhydrase type II isozyme (CA-II), which is involved in aqueous humor secretion.
openaire   +2 more sources

Brinzolamide/Timolol

Drugs & Aging, 2009
Brinzolamide 1%/timolol 0.5% fixed combination (brinzolamide/timolol) is a twice-daily eyedrops suspension comprising the carbonic anhydrase-II inhibitor brinzolamide and the beta-adrenergic receptor antagonist timolol. Brinzolamide/timolol produced clinically relevant reductions in mean intraocular pressure (IOP) from baseline and was more effective ...
Jamie D, Croxtall, Lesley J, Scott
openaire   +2 more sources

Travoprost/timolol/brinzolamide/brinzolamide/timolol

Reactions Weekly, 2023
openaire   +1 more source

Brinzolamide

Reactions Weekly, 2022
openaire   +1 more source

The Efficacy, Safety, and Satisfaction Associated with Switching from Brinzolamide or Brimonidine to Brinzolamide/Brimonidine in Open-Angle Glaucoma Patients

Journal of Personalized Medicine, 2022
Yoshiaki Kiuchi, Kazuyuki Hirooka, Hiromitsu Onoe   +2 more
exaly  

Brinzolamide

2023
openaire   +1 more source

The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients

Journal of Clinical Medicine, 2021
Hideaki Okumichi, Yoshiaki Kiuchi, Kazuyuki Hirooka   +2 more
exaly